The European Medicines Agency’s, EMA, committee recommended a change to extend the use of Eli Lilly’s (LLY) Mounjaro for the treatment of type 2 diabetes, that is not satisfactorily controlled, to adolescents and children from 10 years of age, together with diet and physical activity. In adults, Mounjaro is also used to treat type 2 diabetes and to help individuals with obesity or who are overweight and who have weight-related health problems lose weight and keep their weight under control.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s New Study on LY3549492: A Potential Breakthrough in Obesity Treatment
- Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis?
- Eli Lilly’s New Study on LY4584180: A Potential Game-Changer in Blood Cancer Treatment?
- Eli Lilly’s New Study on Obesity Drug LY4167586: What Investors Need to Know
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer for PAD Treatment